Timolol beta-blockers

Description Results NMA

all cause death 0.48 [0.05; 4.82]

all cause death ∞ [NaN; ∞]

all cause death 0.73 [0.17; 3.14]

all cause death 0.36 [0.04; 3.36]

all cause death 1.10 [0.07; 16.96]

all cause death 0.79 [0.22; 2.77]

all cause death 0.64 [0.51; 0.81]

cardiovascular death 0.58 [0.45; 0.75]

Sudden death 0.49 [0.35; 0.69]

cardiac death 0.58 [0.45; 0.75]

reinfarction 0.62 [0.48; 0.80]

Timolol (initial dose intravenously) (n=20)

vs.

(n=19)

Unclear

Sample size: 20/19

Primary endpoint:

FU duration: In hospital

Timolol (initial dose intravenously) (n=50)

vs.

(n=50)

Unclear

Sample size: 50/50

Primary endpoint:

FU duration: 28 days

Timolol (initial dose intravenously) (n=73)

vs.

(n=71)

Double

Sample size: 73/71

Primary endpoint:

FU duration: To discharge

Timolol (initial dose intravenously) (n=45)

vs.

(n=49)

Double IV open orally

Sample size: 45/49

Primary endpoint:

FU duration: 28 days

Timolol (n=42)

vs.

(n=46)

Double

Sample size: 42/46

Primary endpoint:

FU duration: 1 year

Timolol (n=56)

vs.

(n=55)

Double

Sample size: 56/55

Primary endpoint:

FU duration: To discharge

Timolol 10mg twice daily (n=945)

vs.

placebo (n=939)

Double blind

Parallel groups

Sample size: 945/939

Primary endpoint: NA

FU duration: 17 months